Macular degeneration is not curable. No treatment available today can reverse the damage it causes to the central part of the retina. But depending on the type you have, treatments can slow progression significantly, stabilize your vision for years, or in some cases improve it temporarily. The distinction between the two forms of the disease, dry and wet, determines what options are on the table.
Why a Cure Doesn’t Exist Yet
Age-related macular degeneration is a multifactorial disease, meaning it doesn’t stem from a single broken mechanism that a single treatment could fix. Genetics, immune system activity, oxidative damage, and lipid metabolism all play roles, and researchers still don’t fully understand how these pathways interact. The complement system (part of your immune defense) is the most established contributor, but its exact share of the blame varies from person to person.
The disease is also chronic and progressive. Once the light-sensing cells in your macula are damaged or lost, they don’t regenerate. Treatments can target the processes that cause further damage, but they can’t rebuild tissue that’s already gone. This is the core reason macular degeneration is managed rather than cured: therapies address what’s driving the disease forward, not what it’s already done.
Wet AMD: The Most Treatable Form
Wet (neovascular) AMD accounts for roughly 10% of cases, but it causes the most rapid and severe vision loss. It happens when abnormal blood vessels grow beneath the retina and leak fluid or blood. The standard treatment involves injections into the eye that block a protein called VEGF, which fuels that abnormal vessel growth. These injections are highly effective. In clinical practice, about 92% of patients maintain usable vision (losing fewer than 15 letters on an eye chart) after three years of treatment, and around 73% still hold that threshold at seven years.
The catch is that this isn’t a one-and-done treatment. You’ll need ongoing injections, often starting monthly and then spacing out based on how your eyes respond. This “treat-and-extend” approach tries to find the longest safe interval between visits. Newer versions of these drugs aim to reduce how often you need injections, though none have proven better at improving vision than the originals. Long-term maintenance remains a challenge because missing or delaying treatments can let the disease flare up again.
Gene therapy trials are currently underway that could change this equation. One approach delivers genetic instructions directly into the eye so that retinal cells produce their own anti-VEGF protein continuously, potentially eliminating the need for repeated injections. These are in advanced clinical trials but not yet approved.
Dry AMD: Fewer Options, but Progress
Dry AMD is far more common, making up about 90% of cases. It progresses more slowly and involves the gradual thinning of the macula rather than leaking blood vessels. For decades, there was no treatment at all. That changed in 2023 when the FDA approved two drugs targeting the complement system for geographic atrophy, the advanced stage of dry AMD where patches of retinal cells die off completely.
These treatments slow the expansion of damaged areas but don’t shrink them or restore lost vision. In clinical trials, one drug reduced the growth rate of atrophied areas by 19 to 22% over two years with monthly injections. The other showed reductions of 14 to 27% over 12 months. These are meaningful in slowing progression, but the lack of noticeable vision improvement has limited how widely the drugs have been adopted. For many patients, the benefit is subtle: vision loss happens more slowly, which matters most over years.
Slowing Progression With Supplements
For people with intermediate dry AMD or advanced AMD in one eye, a specific combination of vitamins and minerals has been shown to reduce the risk of progressing to advanced disease by about 25% over five years. Known as the AREDS2 formula, it contains 500 mg of vitamin C, 400 IU of vitamin E, 10 mg of lutein, 2 mg of zeaxanthin, 80 mg of zinc, and 2 mg of copper. The people who benefited most from the lutein and zeaxanthin components were those who didn’t already get much of these nutrients from their diet, where the supplements cut the risk of advanced AMD by 26%.
These supplements don’t help everyone equally. They’re aimed at people who already have moderate disease, not at preventing AMD from developing in the first place.
Risk of Dry AMD Becoming Wet
One concern for people with dry AMD is that it can convert to the wet form. The estimated risk is 1 to 4.7% per year, and 13 to 18% over three years. This is why regular monitoring matters. An Amsler grid, a simple printed grid of straight lines with a center dot, is a daily self-check you can do at home. Hold it 12 to 15 inches from your face in good light, cover one eye, and focus on the center dot. If any lines appear wavy, blurry, dark, or blank, that’s a sign something may have changed and you should contact your eye doctor promptly. Early detection of wet AMD means earlier treatment, which leads to better outcomes.
Lifestyle Factors That Affect Risk
Genetics play a significant role in AMD, but lifestyle choices interact with genetic risk in powerful ways. A National Eye Institute study found that people with a genetic predisposition to AMD who also had a history of heavy smoking and consistently low intake of fruits and vegetables were dramatically more likely to develop the disease. Women with two high-risk genetic variants who smoked heavily and had poor diet and exercise habits were more than four times as likely to develop AMD compared to genetically similar women who ate well and stayed active.
Vitamin D levels add another layer. Deficiency (blood levels below 12 ng/mL) was associated with a 6.7-fold increase in AMD odds among women carrying two genetic risk variants, compared to a 1.8-fold increase among women with no genetic risk. Even moderate physical activity, around 10 hours a week of light exercise like walking, appeared protective when combined with a diet rich in fruits and vegetables.
Living With Vision Loss
When macular degeneration does cause permanent central vision loss, low-vision aids can make a real difference in daily life. These range from simple handheld magnifiers and high-powered reading glasses to portable video magnifiers that can enlarge text up to 25 times its original size and let you switch to high-contrast displays. Spectacle-mounted telescopes help with tasks like watching television or recognizing faces across a room. Electronic devices with adjustable magnification and reverse contrast (light text on a dark background) have been especially effective for people with AMD, improving near vision across all age groups in studies. Peripheral vision is typically preserved even in advanced AMD, so these tools work by helping you make the most of the vision you still have.